Regístrese
Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 18F-FDG-PET/CT in the surveillance of patients with lymphoma: Detection of asymp...
Journal Information
Vol. 31. Issue 1.
Pages 22-27 (January - February 2012)
Share
Share
Download PDF
More article options
ePub
Visits
2352
Vol. 31. Issue 1.
Pages 22-27 (January - February 2012)
Original article
DOI: 10.1016/j.remngl.2011.04.006
18F-FDG-PET/CT in the surveillance of patients with lymphoma: Detection of asymptomatic recurrences
PET-TAC con 18F-FDG en el seguimiento de pacientes con linfoma: detección de recidivas asintomáticas
Visits
...
A.M. García Vicentea,??
Corresponding author
, M. Bellón Guardiaa, A. Soriano Castrejóna, C. Calle Primob, J.M. Cordero Garcíaa, A. Palomar Muñoza, J.P. Pilkington Wolla, M.P. Talavera Rubioa, B. Hernández Ruizb
a Servicio de Medicina Nuclear, Hospital General Universitario, Ciudad Real, Spain
b Servicio de Hematología, Hospital General Universitario, Ciudad Real, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (3)
Table 1. Distribution of patients according to their characteristics on diagnoses and in the group with demonstrated recurrence.
Table 2. Pathological findings with the PET-CT study and their final classification.
Table 3. Statistical diagnostic parameters according to the studies in patients analyzed.
Show moreShow less
Abstract
Aim

To assess the diagnostic accuracy of 18F-FDG-PET/CT in detecting asymptomatic recurrences in patients with lymphoma. To define uptake patterns of recurrence indicative of recurrence.

Material and methods

Those patients with lymphoma who fulfilled the following inclusion criteria of clinical complete remission and negative PET/CT study were included retrospectively and longitudinally. Conventional surveillance of these patients was performed only by 18F-FDG PET/CT following a standardized procedure. Pathologic locations (supra- and infradiaphragmatic) and their character (single or multiple) were analyzed in order to determine reliable metabolic patterns of recurrence. The final diagnosis was established by histopathological analysis or clinical follow-up greater than 8 months.

Results

A total of 199 explorations belonging to 106 patients with lymphoma were included. Of these patients, 59 had Hodgkin's lymphoma and 47 non-Hodgkin's lymphoma. There was suspicion of relapse from the metabolic point of view in 27 of the PET/CT scans. Of these, 14 (10 patients) were false positive (FP), and 13 (8 patients) true positive. The remaining studies were true negative, no false negatives being detected. The pattern most frequently related to recurrence was infradiaphragmatic lymph node involvement while most of the FP had isolated supradiaphragmatic involvement. Sensitivity, specificity, PPV, NPV and diagnostic accuracy of PET/CT parameters for the study were 100%, 92%, 48%, 100% and 93%, respectively.

Conclusion

18F-FDG-PET/CT is a sensitive technique in the detection of asymptomatic recurrences in patients with lymphoma during their follow-up. Multiple character and infradiaphragmatic locations were the patterns that best correlated to the diagnosis of recurrence.

Keywords:
PET/CT
18F-FDG
Lymphoma
Asymptomatic recurrence
Surveillance
Resumen
Objetivos

Determinar la rentabilidad diagnóstica de la PET-TAC con 18F-FDG en la detección de recidivas asintomáticas en pacientes con linfoma. Definir patrones de captación indicativos de recidiva.

Material y métodos

Se incluyeron de forma retrospectiva y longitudinal pacientes afectos de linfoma con los siguientes criterios de inclusión: remisión completa clínica con estudio PET-TAC negativo. Se realizó seguimiento convencional de estos pacientes únicamente mediante PET-TAC con 18F-FDG según técnica estándar. Se analizaron las localizaciones patológicas (supra e infradiafragmáticas) y su carácter (único o múltiple) con vistas a determinar patrones metabólicos fidedignos de recidiva. El diagnóstico final se estableció por análisis histopatológico o seguimiento clínico-radiológico superior a 8 meses.

Resultados

Se incluyeron 199 exploraciones pertenecientes a 106 pacientes, 59 afectos de linfoma de Hodgkin y 47 de linfoma no Hodgkin. Veintisiete estudios fueron indicativos de recidiva desde el punto de vista metabólico. De ellos 14 fueron falsos positivos (FP), 10 pacientes y 13 verdaderos positivos, 8 pacientes. El resto de los estudios fueron verdaderos negativos y no se detectaron falsos negativos. El patrón más frecuentemente relacionado con recidiva fue la afectación adenopática infradiafragmática mientras que la mayoría de los FP poseían afectación supradiafragmática aislada. Los parámetros de sensibilidad, especificidad, VPP, VPN y exactitud diagnóstica por exploración fueron de: 100%, 92%, 48%, 100% y 93% respectivamente.

Conclusión

La PET-TAC con 18F-FDG es una técnica sensible en la detección de recidivas asintomáticas de pacientes con linfoma durante el seguimiento. El carácter múltiple y las localizaciones infradiafragmáticas fueron los parámetros mejor correlacionados con el diagnóstico de recidiva.

Palabras clave:
PET-TAC
18F-FDG
Linfoma
Recidiva asintomática
Seguimiento

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 22,50 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.